Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment.
The pharmaceutical behemoth announced the said partnership at ASCO, the world’s largest cancer conference in Chicago.
Despite today’s price action, BMY shares are down some 25% versus their year-to-date high.
Speaking this morning with CNBC, Christopher Boerner – chief executive of Bristol Myers offered three big reasons for the blockbuster collaboration with the Germany based BioNTech.
1. Targeting hard-to-treat tumors with breakthrough science
According to Christopher Boerner, the BioNTech deal stems from the company’s commitment to one mission: tackling some of the most challenging solid tumours where current treatments fall short.
The collaboration will focus on next-gen immunotherapies, particularly bispecific antibodies that aim to improve outcomes in cancers like lung and triple-negative breast cancer.
“This could be the next new frontier in the treatment of cancer,” Boerner told CNBC, adding that immune-oncology (IO) drugs may have changed the landscape for many cancers, but lasting remission is still seen in about 30% of the patients only.
That leaves a large pool of patients with unmet medical needs – patients that Bristol Myers and BNTX are hoping to reach.
At the core of the announced team-up is a promising drug candidate that combines VEGF and PD-L1 inhibition in a single bispecific molecule, potentially leading to more durable responses.
“We really like the science,” Boerner noted, calling the bispecific approach a potential game-changer.
2. Strategic positioning for first mover advantage in key markets
Beyond the science, the deal is also about gaining a competitive edge.
Boerner highlighted the importance of timing in a crowded oncology market during the interview, saying what he’s learned from his experience in immuno-oncology is “if you want to capture value in highly competitive spaces, you need to be first or second.”
According to the chief executive, BioNTech’s assets are well-positioned to become early entrants across several high-value tumor types.
That timing could give BMY the kind of foothold needed to secure commercial success. The company’s existing expertise in marketing and distributing oncology products further strengthens its chances to maximize the value of the deal.
3. Doubling Down on Long-Term Growth Potential
The BioNTech partnership is not just about short-term results, Boerner sees it as a long-term growth engine for the pharma stock as the decade unfolds.
With some of its legacy IO products facing patent cliffs, BMS needs new therapies to fuel future revenues. This collaboration offers that potential, pairing BioNTech’s cutting-edge science with BMY’s commercialization capabilities.
“This deal gives us another leg for growth as we exit this decade,” Boerner said. With BioNTech’s pipeline complementing Bristol Myers’ strategy, the partnership could evolve into a foundational element of the company’s oncology business.
In a high-stakes, high-reward field, BMY is betting big – but with a clear vision of where the science and market are heading. If successful, the partnership could reshape cancer treatment and deliver billions in future returns.
The post Bristol Myers CEO explains why he’s spending billions on BioNTech deal appeared first on Invezz